Showing results (1591-1600 of 1,671) with videos related to

Sort By:
Pageof 168
Cancer Treatment and Research Communications|May 24, 2021
Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinibDylan J Martini, Meredith R Kline, Yuan Liu, et al.
Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society|March 16, 2023
Minced muscle autografting improves bone healing but not muscle function in a porcine composite injury modelTodd O McKinley, Roman N Natoli, Naveena B Janakiram, et al.
Cancer|August 19, 2007
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cellsMichael W N Deininger, Jorge Cortes, Ron Paquette, et al.
American Journal of Human Genetics|February 17, 2001
A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studiesC M Eng, M Banikazemi, R E Gordon, et al.
Blood|December 12, 2001
The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteinsA Demiroglu, E J Steer, C Heath, et al.
Blood|August 4, 2010
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)Timothy P Hughes, Andreas Hochhaus, Susan Branford, et al.
Transplantation Proceedings|June 15, 2004
Magnetic resonance cholangiography in the diagnosis of biliary complications after orthotopic liver transplantationM M Linhares, A M Gonzalez, S M Goldman, et al.
Genes, Chromosomes & Cancer|September 11, 2001
Identification of four new translocations involving FGFR1 in myeloid disordersJ Sohal, A Chase, S Mould, et al.
Annals of Neurology|November 16, 2011
Solvent exposures and Parkinson disease risk in twinsSamuel M Goldman, Patricia J Quinlan, G Webster Ross, et al.
Blood|August 8, 2008
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trialsSusan Branford, Linda Fletcher, Nicholas C P Cross, et al.
Pageof 168